Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2–Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti–Human Epidermal Growth Factor Receptor 2 Therapy
Pierre Squifflet,Everardo D. Saad,Sibylle Loibl,Marion T. van Mackelenbergh,Michael Untch,Priya Rastogi,Luca Gianni,Andreas Schneeweiss,Pierfranco Conte,Martine Piccart,Hervé Bonnefoi,Christian Jackisch,Valentina Nekljudova,Gong Tang,Pinuccia Valagussa,Colin Neate,Richard Gelber,Coralie Poncet,Dominik Heinzmann,Carsten Denkert,Charles E. Geyer,Javier Cortes,Valentina Guarneri,Evandro de Azambuja,David Cameron,Gustavo Ismael,Norman Wolmark,Patricia Cortazar,Marc Buyse,on behalf of the CTNeoBC Project
DOI: https://doi.org/10.1200/JCO.22.02363
IF: 45.3
2023-03-30
Journal of Clinical Oncology
Abstract:PURPOSE Pathologic complete response (pCR) has prognostic importance and is frequently used as a primary end point, but doubts remain about its validity as a surrogate for event-free survival (EFS) and overall survival (OS) in human epidermal growth factor receptor 2 (HER2)–positive, early breast cancer. METHODS We obtained individual-patient data from randomized trials of neoadjuvant anti-HER2 therapy that enrolled at least 100 patients, had data for pCR, EFS, and OS, and a median follow-up of at least 3 years. We quantified the patient-level association between pCR (defined as ypT0/Tis ypN0) and both EFS and OS using odds ratios (ORs, with ORs >1.00 indicating a benefit from achieving a pCR). We quantified the trial-level association between treatment effects on pCR and on EFS and OS using R 2 (with values above 0.75 considered as indicating strong associations). RESULTS Eleven of 15 eligible trials had data for analysis (3,980 patients, with a median follow-up of 62 months). Considering all trials, we found strong patient-level associations, with ORs of 2.64 (95% CI, 2.20 to 3.07) for EFS and 3.15 (95% CI, 2.38 to 3.91) for OS; however, trial-level associations were weak, with an unadjusted R 2 of 0.23 (95% CI, 0 to 0.66) for EFS and 0.02 (95% CI, 0 to 0.17) for OS. We found qualitatively similar results when grouping trials according to different clinical questions, when analyzing only patients with hormone receptor–negative disease, and when using a more stringent definition of pCR (ypT0 ypN0). CONCLUSION Although pCR may be useful for patient management, it cannot be considered as a surrogate for EFS or OS in neoadjuvant trials of HER2-positive, operable breast cancer.
oncology